moxifloxacin has been researched along with Community Acquired Infection in 112 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 65 (58.04) | 29.6817 |
| 2010's | 35 (31.25) | 24.3611 |
| 2020's | 12 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Alexander, E; Das, AF; File, TM; Gelone, SP; Goldberg, L; Heinrich, S; Moran, GJ; Patel, P; Paukner, S; Sandrock, C; Schranz, J; Vidal, JE; Waites, KB | 1 |
| Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M | 1 |
| Lamb, YN; Lee, A; Shirley, M | 1 |
| Anyfantakis, D; Makrakis, G | 1 |
| Abushanab, L; Alshamayleh, N; Anzueto, A; Arabiat, H; Diab, A; Haddad, G; Jaber, W; Khalil, B; Kufoof, N; Momani, D; Mughrabi, M; Mulhem, A; Obaidat, M; Odat, E; Ramadan, M; Wadi Al Ramahi, J; Zahran, A | 1 |
| Donato, A; Powell, D | 1 |
| Liu, J; Lou, B; She, J; Zhou, B | 1 |
| Cammarata, S; Keedy, K; Lawrence, L; McCurdy, S; Nenninger, A; Quintas, M; Sheets, A | 1 |
| Bozkaya, D; Lodise, TP; Massey, J; Spargo, A; Tillotson, GS | 1 |
| Lai, CC; Tang, HJ; Wang, JH | 1 |
| Curran, M; Das, AF; Eckburg, PB; Garrity-Ryan, L; Kirsch, C; Manley, A; McGovern, PC; Steenbergen, JN; Torres, A; Tzanis, E | 1 |
| LaPensee, K; Lodise, TP; Mistry, R; Young, K | 1 |
| Chen, L; Du, X; Han, Y; Jian, Y; Xuan, J | 1 |
| Chitra, S; McGovern, P; Pai, MP; Wilcox, M | 1 |
| Adamzik, M; Asmussen, S; Karlik, J; Peters, J; Rahmel, T; Steinmann, J | 1 |
| Gu, L; Jia, S; Lai, GX; Liu, W; Wang, AM; Wen, W; Xia, WJ; Yu, GQ; Yu, P; Zeng, H | 1 |
| Das, AF; Eckburg, PB; Garrity-Ryan, L; Gonong, JR; Kirsch, C; Loh, E; Madej, A; Manley, A; McGovern, PC; Mitha, I; Nseir, W; Popescu, M; Steenbergen, JN; Stets, R; Tzanis, E | 1 |
| Chitra, S; Curran, M; Kirsch, C; Manley, A; McGovern, PC; Noble, R; Ramirez, JA; Tzanis, E | 1 |
| Chen, CW; Ma, CJ; Ming, CC; Shan, YS; Wang, JY; Yeh, YS | 1 |
| Noreddin, AM; Salem, AH | 1 |
| Drobot, EI; Kondrashova, NM; Lyapun, IN; Plekhova, NG; Somova, LM | 1 |
| Akata, K; Awaya, Y; Choujin, Y; Inoue, N; Ishimoto, H; Kawajiri, T; Kawanami, Y; Kawanaml, T; Mukae, H; Nagata, S; Nishida, C; Noguchi, S; Obata, H; Ogoshi, T; Orihashi, T; Suzuki, Y; Taura, Y; Tokuyama, S; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C | 1 |
| Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z | 1 |
| Goldstein, RC; Husk, G; Jodlowski, T; Mildvan, D; Perlman, DC; Ruhe, JJ | 1 |
| Bezlepko, A; Iudina, L; Kondova Topuzovska, I; Kuzman, I; Marschall, HP; Petri, T; Rókusz, L | 1 |
| Ci, X; Ding, J; Gao, Y; Shangguan, Z; Sun, Q; Yi, L; Zhan, A; Zhang, M; Zhao, R | 1 |
| Brock, B; Hardlei, TF; Jensen-Fangel, S; Kragh Thomsen, M; Kreilgaard, M; Öbrink-Hansen, K; Petersen, E | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Chang, SH; Chien, HI; Chien, ST; Hsu, CH; Hsueh, JC; Lee, PL; Lee, TM; Yang, MC; Yang, TF | 1 |
| England, BS; Twilla, JD; Van Berkel, MA | 1 |
| Chen, L; Chen, X; Jia, X; Li, N; Liu, W; Sun, H; Tong, H; Xiang, R; Xu, Y; Zhang, F; Zhang, J; Zhao, H | 1 |
| Antonovsky, Y; Barrera, CM; Clark, K; Das, AF; Doreski, PA; Fernandes, P; Flores-Figueroa, J; Horwith, G; Jamieson, B; Karimjee, N; Keedy, K; Metev, H; Mitha, I; Molina, JM; Mykietiuk, A; Nitu, MF; Oldach, D; Rewerska, B; Rowe, BH; Scott, D; Sheets, A; Tanaseanu, CM; Van Rensburg, DJ | 1 |
| Deng, H; Li, J; Li, Q; Wen, R | 1 |
| Das, AF; Fernandes, P; File, TM; Gonong, JRV; Jamieson, BD; Keedy, K; Oldach, D; Rewerska, B; Sheets, A; Taylor, D; Vucinic-Mihailovic, V | 1 |
| Decramer, M; Simoens, S | 1 |
| Anzueto, A; Miravitlles, M | 1 |
| Enoch, DA; Ludlam, HA | 1 |
| Koopmans, RP; Prins, JM | 1 |
| Fang, H; Huang, H; Nord, CE; Weintraub, A | 1 |
| Simoens, S | 1 |
| Chen, MJ; Hampel, B; Ma, EL; Solomkin, J; Zhao, YP | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Liu, CY; Lu, CL | 1 |
| Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE | 1 |
| An, MM; Cao, YB; Gao, PH; Jiang, YY; Shen, H; Zou, Z | 1 |
| Cheadle, W; Lee, JT; Napolitano, LM; Nichols, RL | 1 |
| Arvis, P; Fritsch, A; Garau, J; Read, RC | 1 |
| Schafer, KR; Wispelwey, B | 1 |
| Appelbaum, PC; Glupczynski, Y; Kosowska-Shick, K; Lemaire, S; Tulkens, PM; Van Bambeke, F | 1 |
| Ewig, S; Hecker, H; Marre, R; Suttorp, N; Welte, T | 1 |
| Fukano, H; Hara, H; Kawanishi, M; Kimura, M; Kishimoto, M; Matsushima, T; Moriya, O; Niki, Y; Okimoto, N; Yoneyama, H; Yoshida, K | 1 |
| Bauer, TT; Ernen, C; Hauptmeier, BM; Hecht, J; Lepper, PM; Nüesch, E; Ott, SR; Pletz, MW; Welte, T | 1 |
| Chen, CW; Chen, YH; Hsueh, PR; Huang, CT; Ko, WC; Lau, YJ; Lee, WS; Lee, YJ; Liu, CY; Liu, HD; Liu, JW | 1 |
| Carbonnelle, S; De Bel, A; Dediste, A; Glupczynski, Y; Huang, TD; Jacobs, F; Jordens, P; Lismond, A; Schatt, P; Tulkens, PM; Van Bambeke, F; Verhaegen, J; Verschuren, F | 1 |
| Biedenbach, DJ; Farrell, DJ; Flamm, RK; Jones, RN; Liverman, LC; McIntyre, G | 1 |
| Bai, N; Cai, Y; Chen, LA; Cui, JC; Liang, BB; Liu, YN; Sun, CG; Wang, R; Yu, XH; Yuan, X; Zhao, TM | 1 |
| Duprat-Lomon, I; Lamping, DL; Marquis, P; Marrel, A; Sagnier, PP; Schroter, S | 1 |
| Allouch, PY; Courvalin, P; Decousser, JW; Leclercq, R | 1 |
| Rijnders, BJ | 1 |
| Corris, P; Duprat-Lomon, I; Höffken, G; Kubin, R; Muir, JF; Sagnier, PP; Torres, A | 1 |
| Citron, DM; Goldstein, EJ; Schooley, S; Stein, GE; Tyrrell, KL | 1 |
| Becker, DL; Chancellor, JV; Drummond, MF; Duprat-Lomon, I; Hux, M; Kubin, R; Sagnier, PP | 1 |
| Karpov, OI; Strekachev, AIu; Zaĭtsev, AA | 1 |
| de la Roza, C; Jardim, JR; Miravitlles, M; Obispo, E; Rico, G; Urueta, J; Wolff, M | 1 |
| Choudhri, S; Church, D; Grossman, C; Haverstock, D; Herman-Gnjidic, Z; Lode, H; McGivern, J | 1 |
| Martinez, FJ | 1 |
| Keating, GM; Scott, LJ | 1 |
| Beecroft, MD; Herman-Gnjidic, Z; Marrie, TJ | 1 |
| Choudhri, S; Fogarty, CM; Hamed, K; Katz, E; Larsen, LS; Song, J | 1 |
| Choudhri, SH; Church, D; Haverstock, D; Hoeffken, G; Jackson, P; Larsen, LS; Peloquin, S; Talan, D | 1 |
| Kovács, G; Máthé, A; Tóth, K | 1 |
| Miravitlles, M | 1 |
| Charles, PE; Chavanet, P; Croisier, D; Etienne, M; Lequeu, C; Piroth, L; Portier, H; Pugin, J | 1 |
| Davis, SL; Delgado, G; McKinnon, PS | 1 |
| Niederman, MS | 1 |
| Brambilla, C; Garre, M; Paganin, F; Portier, H; Poubeau, P; Zuck, P | 1 |
| Burdette, SD; Polenakovik, H; Polenakovik, S | 1 |
| Ambler, J; Choudhri, S; Fogarty, C; Haverstock, D; Herrington, J; Torres, A | 1 |
| Bauer, TT; de Zeeuw, J; Ernen, C; Schlosser, BM; Schultze-Werninghaus, G; Thate-Waschke, I; Welte, T | 1 |
| Bauer, TT; Petermann, W; Reimnitz, P; Schürmann, D; Welte, T | 1 |
| Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS | 1 |
| Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI | 1 |
| Leenders, AC | 1 |
| Solnick, JV | 1 |
| Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D | 1 |
| Liu, H; Liu, J; Xiong, S; Xiong, W; Xu, S; Xu, Y; Zhao, J | 1 |
| Bassetti, M; DI Biagio, A; Righi, E; Rosso, R; Tosi, C; Viscoli, C | 1 |
| DeRyke, AC; Fan, HW; Lee, SY; Nicolau, DP; Sutherland, C | 1 |
| Ferrara, AM | 1 |
| Hoban, DJ; Noreddin, AM; Ostroski, M; Reese, AA; Zhanel, GG | 1 |
| Decramer, M; Martin, M; Moore, L; Quilici, S; Simoens, S | 1 |
| Citron, DM; Goldstein, EJC; Rybak, MJ; Tyrrell, KL; Warren, YA | 1 |
| Evers, T; Holman, A; Lloyd, A | 1 |
| Arvis, P; Carlet, J; Choudhri, S; Garau, J; Kureishi, A; Le Berre, MA; Lode, H; Read, RC; Torres, A; Winter, J | 1 |
| Doshi, D; Grant, R; Janagap-Benson, C; Olson, W; Schein, J; Sikirica, V | 1 |
| Lindsell, C; Ryan, RJ; Sheehan, P | 1 |
| Church, D; Haverstock, D; Patel, T; Pearl, J; Williams, J | 1 |
| Balfour, JA; Lamb, HM | 1 |
| Nightingale, CH | 1 |
| Hammerschlag, MR; Roblin, PM | 1 |
| Ball, P | 1 |
| Arvis, P; Marel, M; Moita, J; Petitpretz, P; Urueta, J | 1 |
| Blondeau, JM; Hansen, GT | 1 |
| Hoeffken, G; Meyer, HP; Verhoef, L; Winter, J | 1 |
| Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V | 1 |
| Betlejewska, K; Hryniewicz, W | 1 |
| Fukano, H; Matsushima, T; Miyashita, N; Niki, Y; Yoshida, K | 1 |
| Garau, J; Lode, H | 1 |
| Bobbaers, H; Collins, O; Finch, R; Hoeffken, G; Izquierdo, JL; Kubin, R; McGivern, J; Nikolaides, P; Ogundare, F; Raz, R; Schürmann, D; Zuck, P | 1 |
24 review(s) available for moxifloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Delafloxacin: A Review in Community-Acquired Pneumonia.
Topics: Adult; Anti-Bacterial Agents; Asthma; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Pulmonary Disease, Chronic Obstructive | 2022 |
Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation.
Topics: Community-Acquired Infections; Cost-Benefit Analysis; Humans; Levofloxacin; Moxifloxacin; Pneumonia | 2021 |
Emergency Department Management of a Myasthenia Gravis Patient with Community-Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis?
Topics: Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Disease Progression; Female; Fluoroquinolones; Humans; Minocycline; Moxifloxacin; Myasthenia Gravis; Pneumonia; Tigecycline | 2016 |
A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bronchitis, Chronic; Community-Acquired Infections; Costs and Cost Analysis; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Respiratory Tract Infections; Sinusitis | 2008 |
Moxifloxacin: a respiratory fluoroquinolone.
Topics: Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Respiratory Tract Infections; Sinusitis | 2008 |
Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
Topics: Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Doxycycline; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; United Kingdom | 2008 |
Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Topics: Anti-Bacterial Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Community-Acquired Infections; Cost-Benefit Analysis; Diarrhea; Drug Resistance, Microbial; Economics, Pharmaceutical; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Practice Guidelines as Topic; Quinolines | 2009 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Peritonitis; Quinolines | 2010 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae | 2010 |
Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
Topics: Anti-Bacterial Agents; Asia; Aza Compounds; Community-Acquired Infections; Enterobacteriaceae Infections; Fluoroquinolones; Guidelines as Topic; Humans; Intraabdominal Infections; Moxifloxacin; Quinolines; Treatment Outcome | 2012 |
Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic | 2012 |
[New approaches to antibacterial therapy of infections in the surgical practice].
Topics: Abdominal Abscess; Aza Compounds; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Cross Infection; Ertapenem; Fluoroquinolones; Humans; Lactams; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Surgical Wound Infection | 2003 |
Moxifloxacin: a review of its use in the management of bacterial infections.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Biological Availability; Bronchitis, Chronic; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Half-Life; Humans; Intestinal Absorption; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia; Quinolines; Sinusitis; Tissue Distribution; Topoisomerase II Inhibitors | 2004 |
Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
[Role of moxifloxacin in the treatment of community-acquired pneumonia].
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Legionnaires' Disease; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Radiography; Treatment Outcome | 2004 |
Moxifloxacin in respiratory tract infections.
Topics: Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections | 2005 |
Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin.
Topics: Aza Compounds; Community-Acquired Infections; Disease Management; Drug Resistance, Microbial; Fluoroquinolones; Humans; Infusions, Intravenous; Moxifloxacin; Pneumonia; Quinolines; Quinolones; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Macrolides; Male; Middle Aged; Moxifloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Quinolines; Streptococcus pneumoniae; Treatment Outcome | 2005 |
A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).
Topics: Aged; Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Interactions; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2007 |
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections | 2000 |
Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections | 2000 |
Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Treatment Outcome | 2001 |
Improving care for patients with respiratory tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Bronchitis; Chronic Disease; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Patient Satisfaction; Pneumonia; Quality of Health Care; Quinolines; Sinusitis | 2002 |
34 trial(s) available for moxifloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Topics: Adult; Bacteria; Coinfection; Community-Acquired Infections; Diterpenes; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates | 2022 |
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Legionella pneumophila; Macrolides; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma pneumoniae; Pneumonia, Bacterial; Streptococcus pneumoniae; Young Adult | 2020 |
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Topics: Aged; Anti-Bacterial Agents; Community-Acquired Infections; Diterpenes; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Streptococcus pneumoniae; Taiwan; Thioglycolates; Treatment Outcome | 2020 |
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Tetracyclines | 2021 |
Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.
Topics: Adult; Aged; Body Mass Index; Community-Acquired Infections; Drug Dosage Calculations; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Safety; Tetracyclines; Treatment Outcome | 2021 |
Omadacycline for Community-Acquired Bacterial Pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Infusions, Intravenous; Intention to Treat Analysis; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Tetracyclines | 2019 |
Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Drug Approval; Humans; Internationality; Moxifloxacin; Pneumonia, Bacterial; Predictive Value of Tests; Tetracyclines | 2019 |
Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Analysis of Variance; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Intraabdominal Infections; Logistic Models; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Risk Factors; Sulbactam; Taiwan; Treatment Outcome; Young Adult | 2013 |
Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies | 2014 |
Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Europe; Female; Fluoroquinolones; Humans; Latin America; Macrolides; Male; Middle Aged; Moxifloxacin; North America; Pneumonia, Bacterial; South Africa; Triazoles; Young Adult | 2016 |
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Comorbidity; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Macrolides; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Treatment Outcome; Triazoles | 2016 |
Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Topics: Adult; Anti-Bacterial Agents; Asia; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Peritonitis; Quinolines; Treatment Outcome | 2009 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
Topics: Adult; Aged; Analysis of Variance; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Bacteria; Cohort Studies; Community-Acquired Infections; Computer Simulation; Female; Fluoroquinolones; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Sputum; Streptococcus pneumoniae; Treatment Outcome | 2011 |
Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Health Care Costs; Humans; Length of Stay; Macrolides; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines; Treatment Failure | 2012 |
The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Psychometrics; Quality Assurance, Health Care; Quinolines; Surveys and Questionnaires | 2002 |
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillins; Pneumonia; Quinolines | 2003 |
[A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Latin America; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Streptococcus pneumoniae; Treatment Outcome | 2003 |
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Pneumonia, Bacterial; Quinolines; Retrospective Studies; Treatment Outcome | 2003 |
Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2004 |
Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ceftriaxone; Community-Acquired Infections; Constipation; Drug Therapy, Combination; Emergency Medical Services; Female; Fluoroquinolones; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Nausea; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety; Time Factors; Treatment Outcome | 2004 |
Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Roxithromycin | 2005 |
Moxifloxacin is efficacious for treatment of community-acquired lung abscesses in adults.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Lung Abscess; Male; Middle Aged; Moxifloxacin; Quinolines | 2005 |
Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Female; Fluoroquinolones; Hospitalization; Humans; Injections, Intravenous; Male; Moxifloxacin; Parenteral Nutrition; Pneumonia, Bacterial; Prospective Studies; Quinolines; Remission Induction; Time Factors | 2005 |
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines | 2005 |
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety | 2006 |
Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefoperazone; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome | 2006 |
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Cost-Benefit Analysis; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Length of Stay; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Treatment Outcome | 2000 |
Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Community-Acquired Infections; Fluoroquinolones; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Moxifloxacin; Nasopharynx; Pneumonia, Bacterial; Quinolines | 2000 |
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Treatment Outcome | 2001 |
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Confidence Intervals; Double-Blind Method; Female; Fluoroquinolones; Humans; Liver Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies; Quinolines; Recurrence; Treatment Outcome | 2001 |
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Topics: Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2002 |
55 other study(ies) available for moxifloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary | 2022 |
R on T Phenomenon and Long QTc Syndrome due to Moxifloxacin in a Healthy Female.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Electrocardiography; Female; Humans; Long QT Syndrome; Middle Aged; Moxifloxacin; Pneumonia, Bacterial | 2019 |
Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Pneumonia; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96 h after the first dose.
Topics: Adult; Community-Acquired Infections; Diterpenes; Humans; Moxifloxacin; Pneumonia, Bacterial; Polycyclic Compounds; Thioglycolates | 2020 |
Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Case-Control Studies; Community-Acquired Infections; Female; Humans; Male; Metabolome; Moxifloxacin; Pneumonia; Prognosis; ROC Curve; Severity of Illness Index; Young Adult | 2020 |
The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Drug Costs; Fluoroquinolones; Humans; Models, Economic; Moxifloxacin; Outpatients; Pneumonia, Bacterial | 2020 |
Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Clostridium Infections; Community-Acquired Infections; Hospitalization; Humans; Moxifloxacin; Pneumonia, Bacterial; Tetracyclines | 2021 |
Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
Topics: Adult; Alanine Transaminase; Anti-Bacterial Agents; Aspartate Aminotransferases; beta-Lactams; Bilirubin; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Respiratory Distress Syndrome; Retrospective Studies | 2017 |
Outbreak of mycoplasmal round pneumonia in an adult population: A case series.
Topics: Agglutination Tests; Anti-Bacterial Agents; China; Community-Acquired Infections; Diagnosis, Differential; Disease Outbreaks; Humans; Male; Moxifloxacin; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
Topics: Area Under Curve; Bronchopneumonia; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae | 2014 |
Pathomorphosis of experimental infection in mice, infected by Streptococcus pneumoniae, under the effect of immunotropic drugs.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Animals, Outbred Strains; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Dietary Supplements; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluoroquinolones; Immunologic Factors; Interleukin-2; Lung; Mice; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Spleen; Streptococcus pneumoniae | 2013 |
[Efficacy and safety of moxifloxacin in patients with nursing and healthcare-associated pneumonia].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines | 2013 |
Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bacteria; Ceftriaxone; Cohort Studies; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Young Adult | 2014 |
Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Europe, Eastern; Female; Fluoroquinolones; France; Hospitalization; Humans; Kazakhstan; Kyrgyzstan; Length of Stay; Male; Middle Aged; Middle East; Moxifloxacin; Pneumonia; Prospective Studies; Severity of Illness Index; Young Adult | 2014 |
Mycoplasma pneumoniae infection in hospitalized adult patients with community-acquired pneumonia in China.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibodies, Bacterial; China; Community-Acquired Infections; Female; Fluoroquinolones; Hospitalization; Humans; Lung; Male; Middle Aged; Moxifloxacin; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Prevalence; Radiography; Treatment Outcome; Young Adult | 2014 |
Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Chromatography, High Pressure Liquid; Community-Acquired Infections; Computer Simulation; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Moxifloxacin; Pneumonia; Young Adult | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
Molecular Characterization of Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Isolates in Southern Taiwan.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Moxifloxacin; Staphylococcal Infections; Taiwan | 2015 |
[Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Topics: Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2016 |
[A case of Legionella pneumonia with multiple organ failure].
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Legionella; Legionnaires' Disease; Male; Middle Aged; Moxifloxacin; Multiple Organ Failure; Pneumonia, Bacterial | 2016 |
[Novel side effects of moxifloxacin: making a balanced decision again].
Topics: Adverse Drug Reaction Reporting Systems; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Hepatitis; Humans; Moxifloxacin; Pneumonia; Quinolines; Risk Assessment; Stevens-Johnson Syndrome; Treatment Outcome | 2008 |
Community acquired Clostridium difficile infection due to a moxifloxacin susceptible ribotype 027 strain.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Clostridioides difficile; Community-Acquired Infections; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Ribotyping; Sweden | 2009 |
In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Community-Acquired Infections; Cross Infection; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Peritonitis; Quinolines; Taiwan; Tigecycline | 2009 |
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Costs and Cost Analysis; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Outpatients; Pneumonia; Quinolines; Young Adult | 2010 |
Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Legionella; Legionellosis; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Cell Line; Clindamycin; Community-Acquired Infections; Fluoroquinolones; Humans; Linezolid; Macrophages; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Oxazolidinones; Phagocytosis; Quinolines; Staphylococcal Infections; Trimethoprim, Sulfamethoxazole Drug Combination | 2011 |
Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; beta-Lactams; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Comorbidity; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Streptococcus pneumoniae; Vaccination; Young Adult | 2012 |
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Geography; Haemophilus influenzae; Humans; Inhibitory Concentration 50; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2012 |
In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Data Collection; Drug Resistance, Bacterial; Female; Fluoroquinolones; France; Genes, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Polymerase Chain Reaction; Quinolines; Respiratory Tract Infections | 2002 |
Moxifloxacin for community-acquired pneumonia.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Intensive Care Units; Moxifloxacin; Pneumonia; Quinolines; Randomized Controlled Trials as Topic | 2003 |
Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Community-Acquired Infections; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Respiratory Tract Infections | 2003 |
[Playing it safe in bronchopulmonary infections].
Topics: Anti-Infective Agents; Aza Compounds; Bronchopneumonia; Community-Acquired Infections; Drug Resistance, Multiple; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic | 2003 |
An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluoroquinolones; France; Germany; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic | 2003 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
[Antibiotic therapy of respiratory tract infections. Rapid and good effectiveness].
Topics: Aza Compounds; Community-Acquired Infections; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome | 2004 |
The impact of mechanical ventilation on the moxifloxacin treatment of experimental pneumonia caused by Streptococcus pneumoniae.
Topics: Animals; Area Under Curve; Aza Compounds; Community-Acquired Infections; Disease Models, Animal; Fluoroquinolones; Half-Life; Male; Moxifloxacin; Pneumococcal Infections; Quinolines; Rabbits; Respiration, Artificial | 2005 |
Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Chi-Square Distribution; Community-Acquired Infections; Economics, Pharmaceutical; Female; Fluoroquinolones; Hospitalization; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines; Treatment Outcome | 2005 |
Cost analyses of community-acquired pneumonia from the hospital perspective.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Cohort Studies; Community-Acquired Infections; Comorbidity; Costs and Cost Analysis; Female; Fluoroquinolones; Germany; Hospitals, Community; Humans; Male; Moxifloxacin; Pneumonia; Quinolines; Smoking | 2005 |
Treatment of hospitalized patients with community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Hospitalization; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2006 |
Treatment with moxifloxacin versus standard therapy for community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Quinolines | 2006 |
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2006 |
Moxifloxacin in the treatment of hospitalised community acquired pneumonia in HIV-infected subjects.
Topics: Adult; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; HIV Infections; Hospitalization; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2007 |
Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Culture Media; Epithelium; Fluoroquinolones; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2007 |
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gemifloxacin; Humans; Monte Carlo Method; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Respiratory Mucosa | 2007 |
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; Cefuroxime; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2008 |
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Community-Acquired Infections; Cross Infection; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Soft Tissue Infections; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcus aureus; Virulence; Virulence Factors | 2008 |
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Female; Fluoroquinolones; Health Care Costs; Hospitalization; Humans; Infusions, Intravenous; Insurance Claim Review; Length of Stay; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Research Design; Retrospective Studies; Treatment Outcome; United States | 2008 |
Fluoroquinolone resistance during 2000-2005: an observational study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Drug Utilization; Enterobacter aerogenes; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pharmacy Service, Hospital; Pneumonia, Bacterial; Quinolines | 2008 |
Gatifloxacin and moxifloxacin: two new fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gastrointestinal Diseases; Gatifloxacin; Humans; Moxifloxacin; Pneumonia; Quinolines; Staphylococcus aureus | 2000 |
Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
Topics: Anti-Infective Agents; Aza Compounds; Bronchitis; Chronic Disease; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2000 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillin Resistance; Poland; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2002 |
In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydia; Community-Acquired Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2002 |